Daniel H. Zimmerman

954 total citations
54 papers, 761 citations indexed

About

Daniel H. Zimmerman is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Daniel H. Zimmerman has authored 54 papers receiving a total of 761 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Immunology, 15 papers in Radiology, Nuclear Medicine and Imaging and 14 papers in Molecular Biology. Recurrent topics in Daniel H. Zimmerman's work include Immunotherapy and Immune Responses (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and T-cell and B-cell Immunology (11 papers). Daniel H. Zimmerman is often cited by papers focused on Immunotherapy and Immune Responses (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and T-cell and B-cell Immunology (11 papers). Daniel H. Zimmerman collaborates with scholars based in United States, Canada and Poland. Daniel H. Zimmerman's co-authors include Milton Kern, Ken S. Rosenthal, Stephen H. Gregory, Kenneth S. Rosenthal, Katalin Mikecz, John J. Docherty, Adrienn Markovics, Earl W. Sutherland, Walter I. Horne and David A. Elliott and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel H. Zimmerman

51 papers receiving 684 citations

Peers

Countries citing papers authored by Daniel H. Zimmerman

Since Specialization

Citations

This map shows the geographic impact of Daniel H. Zimmerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel H. Zimmerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel H. Zimmerman more than expected).

Fields of papers citing papers by Daniel H. Zimmerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel H. Zimmerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel H. Zimmerman. The network helps show where Daniel H. Zimmerman may publish in the future.

Co-authorship network of co-authors of Daniel H. Zimmerman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel H. Zimmerman. A scholar is included among the top collaborators of Daniel H. Zimmerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel H. Zimmerman. Daniel H. Zimmerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines 2024 ·Frontiers in Immunology ·Daniel H. Zimmerman, Zoltán Szekanecz, Adrienn Markovics, Kenneth S. Rosenthal, (unknown), Katalin Mikecz	3
2	Lessons from next generation influenza vaccines for inflammatory disease therapies 2019 ·International Immunopharmacology ·Daniel H. Zimmerman, (unknown), (unknown), Ken S. Rosenthal	4
3	J-LEAPS vaccines elicit antigen specific Th1 responses by promoting maturation of type 1 dendritic cells (DC1) 2017 ·SHILAP Revista de lepidopterología ·Ken S. Rosenthal, Daniel H. Zimmerman	2
4	An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis 2017 ·Vaccine ·Katalin Mikecz, Tibor T. Glant, Adrienn Markovics, Kenneth S. Rosenthal, Júlia Kurkó, (unknown), (unknown), (unknown), Daniel H. Zimmerman	18
5	Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis 2015 ·Expert Review of Vaccines ·Kenneth S. Rosenthal, Katalin Mikecz, (unknown), Tibor T. Glant, Alison Finnegan, (unknown), Daniel H. Zimmerman	24
6	A Balanced IL-1β Activity Is Required for Host Response to Citrobacter rodentium Infection 2013 ·PLoS ONE ·Misagh Alipour, Yuefei Lou, Daniel H. Zimmerman, Michael Bording‐Jorgensen, Consolato Sergi, Julia J. Liu, Eytan Wine	39
7	LEAPS Therapeutic Vaccines as Antigen Specific Suppressors of Inflammation in Infectious and Autoimmune Diseases 2012 ·Journal of Vaccines & Vaccination ·Daniel H. Zimmerman	6
8	J‐LEAPS peptide and LEAPS dendritic cell vaccines 2011 ·Microbial Biotechnology ·Ken S. Rosenthal, Patricia R. Taylor, Daniel H. Zimmerman	13
9	J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells 2010 ·Vaccine ·Philip R. Taylor, Gary K. Koski, Christopher Paustian, Erin Bailey, P A Cohen, Francisco B.‐G. Moore, Daniel H. Zimmerman, Ken S. Rosenthal	19
10	CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model 2010 ·International Immunopharmacology ·Daniel H. Zimmerman, (unknown), Alison M. Bendele, (unknown), (unknown), (unknown), (unknown), (unknown), Kenneth S. Rosenthal	30
11	L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart 2008 ·International Immunopharmacology ·Daniela Čiháková, Jobert G. Barin, G. Christian Baldeviano, Miho Kimura, Monica V. Talor, Daniel H. Zimmerman, (unknown), Noel R. Rose	13
12	CEL-1000—a peptide with adjuvant activity for Th1 immune responses 2004 ·Vaccine ·Yupin Charoenvit, (unknown), Michael Whelan, Kenneth S. Rosenthal, Daniel H. Zimmerman	14
13	A modification of the epidermal scarification model of herpes simplex virus infection to achieve a reproducible and uniform progression of disease 2002 ·Journal of Virological Methods ·(unknown), John J. Docherty, Ming Fu, Daniel H. Zimmerman, Kenneth S. Rosenthal	8
14	The ability of an HSV strain to initiate zosteriform spread correlates with its neuroinvasive disease potential 2002 ·Archives of Virology ·(unknown), Hongyi Mao, (unknown), John J. Docherty, Daniel H. Zimmerman, Ken S. Rosenthal	18
15	Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine 2002 ·Vaccine ·В. М. Писарев, Prahlad Parajuli, R. Lee Mosley, Jennifer Chavez, Daniel H. Zimmerman, (unknown), James E. Talmadge	14
16	Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine 2000 ·International Journal of Immunopharmacology ·В. М. Писарев, Prahlad Parajuli, R. Lee Mosley, (unknown), Linda Kelsey, Prem S. Sarin, Daniel H. Zimmerman, (unknown), James E. Talmadge	18
17	Immunization with a LEAPS™ heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1 1999 ·Vaccine ·Ken S. Rosenthal, (unknown), Walter I. Horne, (unknown), Daniel H. Zimmerman	40
18	Cross-Clade p17 Peptide Recognition by Antisera to HGP-30, a 30-Amino Acid Synthetic Peptide Antigen from HIV Type 1 p17 1998 ·AIDS Research and Human Retroviruses ·Daniel H. Zimmerman, J. Terry Ulrich, Craig Wright, (unknown), (unknown), P. S. Sarin	7
19	Hail and Farewell 1988 ·Science News ·Daniel H. Zimmerman	1
20	The biosynthesis of plasma lipoproteins in higher animals 1968 ·Comparative Biochemistry and Physiology ·Melvin Fried, Henry G. Wilcox, Gerald R. Faloona, (unknown), (unknown), Daniel H. Zimmerman	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact